COMMUNIQUÉS West-GlobeNewswire

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
10/02/2025
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. ( [...]
SoldierStrong Joins Forces With Patriot Mobile to Assist Military Veterans in Taking Their Next Steps Forward
10/02/2025
STAMFORD, Conn., Feb. 10, 2025 (GLOBE NEWSWIRE) -- SoldierStrong, a national nonprofit dedicated to providing revolutionary medical technology to U.S. Department of Veterans Affairs medical facilities and individual [...]
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
10/02/2025
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its [...]
Capricor Therapeutics to Participate in Upcoming Investor Conferences
10/02/2025
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
10/02/2025
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/ [...]
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
10/02/2025
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and real-world outcomes [...]
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
10/02/2025
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE [...]
Oncocyte Prices $29.1 Million Equity Offering
10/02/2025
Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE [...]
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
10/02/2025
Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “ [...]
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
10/02/2025
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal [...]
KFSHRC Detects 276 Fetal Genetic Disorders Through Prenatal Care Saving SAR 360 Million Annually
10/02/2025
RIYADH, Saudi Arabia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is enhancing prenatal care through innovation and precision medicine. By testing more than 300 genes [...]
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
10/02/2025
TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
10/02/2025
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus placebo The [...]
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
10/02/2025
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc [...]
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
10/02/2025
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an [...]
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
10/02/2025
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease [...]
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
10/02/2025
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. [...]
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
10/02/2025
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Mustang Bio Announces Closing of $8 Million Public Offering
10/02/2025
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]

Pages